Change - Announcement of Appointment::Announcement of Appointment of Executive Director and Chief Executive Officer

Issuer & Securities

Issuer/ Manager
LIVINGSTONE HEALTH HOLDINGS LIMITED
Securities
LIVINGSTONE HEALTH HLDGS LTD - SGXE70643320 - PRH
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
05-Feb-2021 00:42:35
Status
New
Announcement Sub Title
Announcement of Appointment of Executive Director and Chief Executive Officer
Announcement Reference
SG210205OTHRH3K6
Submitted By (Co./ Ind. Name)
Teh Wing Kwan
Designation
Executive Chairman and Chief Executive Officer
Description (Please provide a detailed description of the event in the box below)
Announcement of Appointment of Executive Director and Chief Executive Officer

This announcement has reviewed by the Company's sponsor, SAC Capital Private Limited ("Sponsor"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Tay Sim Yee, SAC Capital Private Limited at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542, Telephone (65) 6232 3210.

Additional Details

Date Of Appointment
04/02/2021
Name Of Person
Tay Ching Yit, Wilson
Age
42
Country Of Principal Residence
Singapore
The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process)
The Board of Directors, having considered the recommendation of the Nominating Committee and having reviewed and considered the qualifications, working experience and suitability of Dr. Tay Ching Yit, Wilson ("Dr. Wilson Tay"), is of the view that Dr. Wilson Tay has the requisite experience and capability to assume the responsibility as Executive Director and Chief Executive Officer of the Company.

Accordingly, the Board of Directors approved the appointment of Dr. Wilson Tay as Executive Director and Chief Executive Officer of the Company.
Whether appointment is executive, and if so, the area of responsibility
Executive, Chief Executive Officer
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Executive Director and Chief Executive Officer
Professional qualifications
1. Registered Medical Specialist at Singapore Medical Council
2. Fellow at the Academy of Medicine, Singapore
3. Certified Interventional Pain Sonologist from World Institute of Pain, United States of America
4. Fellow of Interventional Pain Practice at World Institute of Pain, United States of America
5. Master of Medicine (Anaesthesiology) from National University of Singapore
6. Diploma in Acupuncture from Singapore College of Traditional Chinese Medicine
7. Bachelor of Medicine and Bachelor of Surgery from National University of Singapore
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
Yes, Dr. Wilson Tay has a 34.8% direct interest in Livingstone Health Consolidated Pte. Ltd., a controlling shareholder holding approximately 215,311,056 shares in the Company.
Conflict of interests (including any competing business)
Dr. Wilson Tay is employed as the Chief Executive Officer, anaesthesiologist and pain management physician under the LSH Group.

Dr. Wilson Tay is a minority shareholder of Diagnostix Imaging, providing diagnostic imaging services such as MRI scans. Dr Wilson Tay does not have an executive or management role in Diagnostix Imaging or its business.
Working experience and occupation(s) during the past 10 years
1. January 2020 - Present: Chief Executive Officer and Executive Director at Livingstone Health Ltd.
2. December 2018 - December 2019: Chief Operating Officer at Livingstone Health Ltd.
3. September 2015 - Present: Anaesthesiologist and Pain Management Physician at Apicare Pain Specialist Pte. Ltd. and Apicare Medical Pte. Ltd.
4. October 2014 - December 2016: Visiting Consultant at Singapore General Hospital (Anaesthesia)
5. October 2014 - August 2015: Consultant at Singapore Paincare Centre
6. May 2013 - September 2014: Consultant (Anaesthesia) at Singapore General Hospital
7. June 2011 - April 2013: Associate Consultant (Anaesthesia) at Singapore General Hospital
8. May 2004 - May 2011: Registrar (Anaesthesia), Medical Officer and House Officer at Singapore Health Services Pte. Ltd.
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
Yes, Dr. Wilson Tay has deemed interest in the shares of the Company by virtue of his 34.8% shareholding of Livingstone Health Consolidated Pte. Ltd., a controlling shareholder holding approximately 215,311,056 shares in the Company.
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
Directorships
- DC Brothers Private Limited

Other Principal Commitments
None
Present
Directorships
- Livingstone Health Consolidated Pte. Ltd.
- Livingstone Endocrine Pte. Ltd.
- The Bone and Joint Centre Pte. Ltd.
- Phoenix Medical Group Pte. Ltd.
- Cove Sports & Reconstruction Pte. Ltd.
- Livingstone Cardiology Pte. Ltd.
- Livingstone Health Ltd.
- Apicare Pain Specialist Pte. Ltd.
- Apicare Medical Pte. Ltd.

Other Principal Commitments
None
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
Dr Wilson Tay has attended the requisite training (LED 1, LED 2, LED 3 and LED 4) conducted by the Singapore Institute of Directors, as prescribed by the Catalist Rules.

Dr Wilson Tay has also attended a briefing conducted by the Legal Adviser on Singapore Law on the Proposed Transactions on the roles and responsibilities of a director, and continuing listing and disclosure obligations.
Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)
Not Applicable